Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL2846 in radioiodine-refractory differentiated thyroid cancer after VEGFR-targeted therapy failure
NCT06860971Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vilzemetkib in differentiated thyroid carcinoma (DTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2025; status: recruiting.
02
Drugs
vilzemetkib
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT06860971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860971.